8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 13, 2026·SEC
Material company update
Mar 3, 2026·SEC
Evolus, Inc.(EOLS)Earnings, Financials & Key Ratios
EOLS•NASDAQ
Price updated Jun 19, 2026
AboutEvolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Show more
- Revenue$297M+11.6%
- EBITDA-$29M-1.6%
- Net Income-$52M-2.4%
- EPS (Diluted)-0.80+1.2%
- Gross Margin64.86%-5.3%
- EBITDA Margin-9.71%+8.9%
- Operating Margin-12.65%+2.1%
- Net Margin-17.38%+8.2%
EOLS Key Insights
Evolus, Inc. (EOLS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 20.5%
- ✓Momentum leader: RS Rating 85 (top 15%)
- ✓Strong 5Y sales CAGR of 39.4%
- ✓Efficient asset utilization: 1.3x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EOLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EOLS Price & Volume
Evolus, Inc. (EOLS) stock price & volume — 10-year historical chart
Loading chart...
EOLS Growth Metrics
Evolus, Inc. (EOLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years39.36%
3 Years25.98%
TTM9.42%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.94%
Return on Capital
10 Years-51.75%
5 Years-32.02%
3 Years-27.28%
Last Year-23.49%
EOLS Recent Earnings
Evolus, Inc. (EOLS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.10+28.6%
$0.14
Rev
$73M+0.8%
$73M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.04-26.3%
$0.06
Rev
$90M+0.9%
$90M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.14+26.3%
$0.19
Rev
$69M-23.0%
$90M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.24-166.7%
$0.09
Rev
$69M-18.7%
$85M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.10vs $0.14+28.6% | $73Mvs $73M+0.8% |
| Q2 2026 | Mar 3, 2026 | $0.04vs $0.06-26.3% | $90Mvs $90M+0.9% |
| Q4 2025 | Nov 5, 2025 | $0.14vs $0.19+26.3% | $69Mvs $90M-23.0% |
| Q3 2025 | Aug 5, 2025 | $0.24vs $0.09-166.7% | $69Mvs $85M-18.7% |
Based on last 12 quarters of dataView full earnings history →
EOLS Peer Comparison
Evolus, Inc. (EOLS) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 ACLX | 6.73B | 115.07 | -28.27 | -79.35% | -10.27% | -55.42% | 0.24 | |
 SKIN | 85.9M | 0.66 | -4.14 | -10.02% | -2.03% | -9.41% | 6.20 | |
 INMD | 849.01M | 13.40 | 9.37 | -6.16% | 23.27% | 13.28% | 0.02 | |
 AVAH | 1.7B | 7.79 | 7.42 | 20.19% | 10.37% | 241.47% | 6.91 | |
 MLAB | 525.42M | 95.10 | 78.60 | 3.38% | 2.69% | 3.71% | 0.48 | |
 IQV | 28.47B | 167.77 | 21.40 | 5.87% | 8.33% | 22.11% | 2.44 | |
 MCK | 90.23B | 750.63 | 19.56 | 12.36% | 1.18% |
Compare EOLS vs Peers
Evolus, Inc. (EOLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EOLS Income Statement
Evolus, Inc. (EOLS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 34.92M | 56.54M | 99.67M | 148.62M | 202.09M | 266.27M | 297.18M | 301.4M |
Revenue Growth % | - | - | - | 61.89% | 76.29% | 49.1% | 35.98% | 31.76% | 11.61% | 9.42% |
Cost of Goods Sold | 218K | 9K | 8.01M | 18.3M | 43.53M | 58.84M | 61.56M | 83.97M | 104.41M | 106.4M |
COGS % of Revenue | - | - | 22.95% | 32.36% | 43.68% | 39.59% | 30.46% | 31.54% | 35.14% | - |
Gross Profit | -218K▲ 0% | -9K▲ 95.9% | 26.91M▲ 299111.1% | 38.24M▲ 42.1% | 56.14M▲ 46.8% | 89.77M▲ 59.9% | 140.53M▲ 56.5% | 182.3M▲ 29.7% | 192.76M▲ 5.7% | 197.9M▲ 0% |
Gross Margin % | - | - | 77.05% | 67.64% | 56.32% | 60.41% | 69.54% | 68.46% | 64.86% | 65.66% |
Gross Profit Growth % | 33.13% | 95.87% | 299111.11% | 42.1% | 46.8% | 59.91% | 56.53% | 29.73% | 5.74% | - |
Operating Expenses | 11.73M | 35.64M | 125.86M | 191.31M | 100.54M | 155.1M | 189.76M | 216.72M | 230.36M | 225.23M |
OpEx % of Revenue | - | - | 360.37% | 338.36% | 100.87% | 104.37% | 93.9% | 81.39% | 77.52% | - |
Selling, General & Admin | 4.82M | 29.15M | 113.59M | 98.19M | 112.07M | 141.84M | 164.94M | 198.03M | 220.79M | 216.13M |
SG&A % of Revenue | - | - | 325.25% | 173.66% | 112.44% | 95.44% | 81.62% | 74.37% | 74.29% | - |
Research & Development | 6.69M | 6.49M | 3.97M | 1.72M | 2.06M | 6.74M | 15.43M | 9.17M | 9.58M | 9.6M |
R&D % of Revenue | - | - | 11.38% | 3.05% | 2.07% | 4.54% | 7.63% | 3.44% | 3.22% | - |
Other Operating Expenses | -5K | 0 | 8.29M | 91.4M | -13.59M | 6.52M | 9.39M | 9.52M | 0 | 0 |
Operating Income | -11.73M▲ 0% | -46.14M▼ 293.5% | -98.95M▼ 114.4% | -153.07M▼ 54.7% | -44.41M▲ 71.0% | -65.33M▼ 47.1% | -49.23M▲ 24.6% | -34.41M▲ 30.1% | -37.6M▼ 9.3% | -28.85M▲ 0% |
Operating Margin % | - | - | -283.31% | -270.73% | -44.55% | -43.96% | -24.36% | -12.92% | -12.65% | -9.57% |
Operating Income Growth % | 41.27% | -293.5% | -114.44% | -54.7% | 70.99% | -47.12% | 24.64% | 30.11% | -9.27% | - |
EBITDA | -11.51M | -46.13M | -93.94M | -145.39M | -38.09M | -61.61M | -43.37M | -28.39M | -28.86M | -20.72M |
EBITDA Margin % | - | - | -268.98% | -257.14% | -38.22% | -41.45% | -21.46% | -10.66% | -9.71% | -6.88% |
EBITDA Growth % | 41.41% | -300.88% | -103.63% | -54.76% | 73.8% | -61.74% | 29.61% | 34.53% | -1.64% | 40.12% |
D&A (Non-Cash Add-back) | 218K | 9K | 5M | 7.68M | 6.31M | 3.72M | 5.87M | 6.02M | 8.74M | 8.13M |
EBIT | -11.73M | -45.94M | -97.11M | -152.43M | -45.37M | -57.58M | -47.68M | -31.02M | -37.6M | -21.65M |
Net Interest Income | 0 | -660K | -6.11M | -9.87M | -1.4M | -8.98M | -12.97M | -15.47M | -17.76M | -14.06M |
Interest Income | 0 | 203K | 1.84M | 635K | 1K | 119K | 860K | 3.26M | 1.93M | 1.51M |
Interest Expense | 0 | 863K | 7.95M | 10.5M | 1.4M | 9.1M | 13.83M | 18.73M | 19.69M | 11.3M |
Other Income/Expense | -5K | -660K | -6.11M | -9.87M | -2.36M | -8.99M | -12.28M | -15.35M | -13.36M | -13.71M |
Pretax Income | -11.73M▲ 0% | -46.8M▼ 299.0% | -105.06M▼ 124.5% | -162.94M▼ 55.1% | -46.77M▲ 71.3% | -74.32M▼ 58.9% | -61.51M▲ 17.2% | -49.76M▲ 19.1% | -50.96M▼ 2.4% | -42.56M▲ 0% |
Pretax Margin % | - | - | -300.82% | -288.18% | -46.92% | -50.01% | -30.44% | -18.69% | -17.15% | -14.12% |
Income Tax | -7.25M | 65K | -15.03M | 77K | 42K | 95K | 176K | 664K | 677K | 349K |
Effective Tax Rate % | 61.81% | -0.14% | 14.3% | -0.05% | -0.09% | -0.13% | -0.29% | -1.33% | -1.33% | -0.82% |
Net Income | -4.48M▲ 0% | -46.87M▼ 946.1% | -90.03M▼ 92.1% | -163.01M▼ 81.1% | -46.81M▲ 71.3% | -74.41M▼ 59.0% | -61.69M▲ 17.1% | -50.42M▲ 18.3% | -51.64M▼ 2.4% | -43.42M▲ 0% |
Net Margin % | - | - | -257.79% | -288.31% | -46.96% | -50.07% | -30.52% | -18.94% | -17.38% | -14.41% |
Net Income Growth % | 77.67% | -946.14% | -92.11% | -81.06% | 71.28% | -58.97% | 17.1% | 18.26% | -2.42% | 22.74% |
Net Income (Continuing) | -4.48M | -46.87M | -90.03M | -163.01M | -46.81M | -74.41M | -61.69M | -50.42M | -51.64M | -43.42M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.19▲ 0% | -1.92▼ 910.5% | -3.19▼ 66.1% | -4.83▼ 51.4% | -0.94▲ 80.5% | -1.33▼ 41.5% | -1.08▲ 18.8% | -0.81▲ 25.0% | -0.80▲ 1.2% | -0.67▲ 0% |
EPS Growth % | 82.41% | -910.53% | -66.15% | -51.41% | 80.54% | -41.49% | 18.8% | 25% | 1.23% | 24.94% |
EPS (Basic) | -0.19 | -1.92 | -3.19 | -4.83 | -0.94 | -1.33 | -1.08 | -0.81 | -0.80 | - |
Diluted Shares Outstanding | 23.59M | 24.4M | 28.24M | 33.74M | 49.77M | 56.07M | 56.92M | 62.02M | 64.47M | 65.19M |
Basic Shares Outstanding | 23.59M | 24.4M | 28.24M | 33.74M | 49.77M | 56.07M | 56.92M | 62.02M | 64.47M | 65.19M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EOLS Balance Sheet
Evolus, Inc. (EOLS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 72.82M | 94.34M | 152.2M | 127.61M | 178.8M | 100.8M | 112.42M | 151.34M | 142.92M | 138.92M |
Cash & Short-Term Investments | 0 | 93.16M | 129.8M | 107.56M | 146.26M | 53.92M | 62.84M | 86.95M | 53.83M | 49.79M |
Cash Only | 0 | 93.16M | 109.89M | 102.56M | 146.26M | 53.92M | 62.84M | 86.95M | 53.83M | 49.79M |
Short-Term Investments | 0 | 0 | 19.91M | 5M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 72.64M | 0 | 10.66M | 9.68M | 14.66M | 22.45M | 30.53M | 47.68M | 54.7M | 52.22M |
Days Sales Outstanding | - | - | 111.42 | 62.49 | 53.67 | 55.13 | 55.14 | 65.36 | 67.18 | 62.08 |
Inventory | 0 | 0 | 6.41M | 3.35M | 1.76M | 18.85M | 11M | 12.16M | 26.96M | 24.8M |
Days Inventory Outstanding | - | - | 291.81 | 66.9 | 14.77 | 116.94 | 65.21 | 52.85 | 94.25 | 95.27 |
Other Current Assets | 0 | 1.18M | 0 | 2.19M | 11.04M | 1.68M | 2.36M | 1.2M | 7.43M | 12.12M |
Total Non-Current Assets | 79.41M | 77.5M | 88.25M | 81.46M | 78.68M | 77.18M | 76.58M | 81.23M | 82.95M | 81.72M |
Property, Plant & Equipment | 0 | 0 | 4.97M | 4.71M | 4.09M | 4.56M | 7.85M | 10.41M | 0 | 0 |
Fixed Asset Turnover | - | - | 7.03x | 12.00x | 24.35x | 32.57x | 25.74x | 25.59x | - | 50.07x |
Goodwill | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M |
Intangible Assets | 56.08M | 56.08M | 59.64M | 55.3M | 50.63M | 48.6M | 47.11M | 48.75M | 48.04M | 46.74M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2.13M | 221K | 2.43M | 240K | 2.76M | 2.81M | 409K | 858K | 13.7M | 13.77M |
Total Assets | 152.23M▲ 0% | 171.84M▲ 12.9% | 240.44M▲ 39.9% | 209.07M▼ 13.0% | 257.48M▲ 23.2% | 177.98M▼ 30.9% | 189M▲ 6.2% | 232.57M▲ 23.1% | 225.87M▼ 2.9% | 220.65M▲ 0% |
Asset Turnover | - | - | 0.15x | 0.27x | 0.39x | 0.84x | 1.07x | 1.14x | 1.32x | 1.35x |
Asset Growth % | 96.44% | 12.88% | 39.92% | -13.05% | 23.16% | -30.88% | 6.19% | 23.05% | -2.88% | -6.21% |
Total Current Liabilities | 212.75M | 5.28M | 24.44M | 180.25M | 57.66M | 46.51M | 48.29M | 62.96M | 75.31M | 68.02M |
Accounts Payable | 445K | 1.56M | 5.8M | 9.62M | 6.09M | 8.94M | 4.27M | 9.24M | 23.36M | 0 |
Days Payables Outstanding | 745.07 | 63.19K | 263.98 | 191.79 | 51.07 | 55.42 | 25.32 | 40.15 | 81.66 | 59.72 |
Short-Term Debt | 211.33M | 0 | 0 | 93.45M | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 1.71M | 3.08M | 7.93M | 9.01M | 11.03M | 14.45M | 0 | 17.31M |
Other Current Liabilities | 0 | 1.14M | 0 | 0 | 0 | 0 | 18.18M | 0 | 49.42M | 68.02M |
Current Ratio | 0.34x | 17.88x | 6.23x | 0.71x | 3.10x | 2.17x | 2.33x | 2.40x | 1.90x | 2.04x |
Quick Ratio | 0.34x | 17.88x | 5.97x | 0.69x | 3.07x | 1.76x | 2.10x | 2.21x | 1.54x | 1.68x |
Cash Conversion Cycle | - | - | 139.25 | -62.39 | 17.38 | 116.65 | 95.03 | 78.06 | 79.78 | 97.64 |
Total Non-Current Liabilities | 15.03M | 82.18M | 136.55M | 101.78M | 117.94M | 112.97M | 161.4M | 164.09M | 173.67M | 181.4M |
Long-Term Debt | 0 | 16.9M | 91.45M | 40.51M | 71.22M | 71.88M | 120.36M | 121.51M | 146.1M | 156.41M |
Capital Lease Obligations | 0 | 0 | 3.89M | 3.15M | 2.26M | 1.22M | 4.81M | 6.75M | 6.37M | 20.05M |
Deferred Tax Liabilities | 14.99M | 15.05M | 0 | 25K | 40K | 22K | 27K | 6K | 28K | 49K |
Other Non-Current Liabilities | 38K | 50.23M | 41.2M | 58.1M | 44.43M | 39.85M | 36.2M | 35.82M | 21.17M | 24.99M |
Total Liabilities | 227.78M | 87.46M | 160.99M | 282.03M | 175.61M | 159.48M | 209.69M | 227.05M | 248.97M | 249.43M |
Total Debt | 211.33M | 16.9M | 96.55M | 138.32M | 74.74M | 74.42M | 126.55M | 129.98M | 155M | 156.41M |
Net Debt | 211.33M | -76.26M | -13.35M | 35.76M | -71.51M | 20.5M | 63.71M | 43.03M | 101.17M | 106.62M |
Debt / Equity | - | - | 1.22x | - | 0.91x | 4.02x | - | 23.54x | - | -5.43x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -7.55x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -5.15x |
Interest Coverage | - | -53.23x | -12.21x | -14.51x | -32.50x | -6.33x | -3.45x | -1.66x | -1.91x | -1.92x |
Total Equity | -75.54M▲ 0% | -123.03M▼ 62.9% | 79.46M▲ 164.6% | -72.96M▼ 191.8% | 81.88M▲ 212.2% | 18.5M▼ 77.4% | -20.69M▼ 211.8% | 5.52M▲ 126.7% | -23.11M▼ 518.4% | -28.78M▲ 0% |
Equity Growth % | -963.09% | -62.85% | 164.59% | -191.82% | 212.22% | -77.41% | -211.84% | 126.69% | -518.44% | -1639.1% |
Book Value per Share | -3.20 | -5.04 | 2.81 | -2.16 | 1.64 | 0.33 | -0.36 | 0.09 | -0.36 | -0.44 |
Total Shareholders' Equity | -75.54M | -123.03M | 79.46M | -72.96M | 81.88M | 18.5M | -20.69M | 5.52M | -23.11M | -28.78M |
Common Stock | 0 | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K |
Retained Earnings | -75.54M | -123.03M | -213.06M | -376.07M | -422.88M | -497.29M | -558.98M | -609.4M | -661.04M | -671.71M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 6K | 0 | 0 | -337K | -427K | -905K | -156K | -278K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EOLS Cash Flow Statement
Evolus, Inc. (EOLS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -13.04M | -25.67M | -93.38M | -57.87M | -33.39M | -84.91M | -34.01M | -18M | -42.27M | -36.59M |
Operating CF Margin % | - | - | -267.38% | -102.35% | -33.5% | -57.14% | -16.83% | -6.76% | -14.22% | - |
Operating CF Growth % | 1.75% | -96.91% | -263.83% | 38.03% | 42.31% | -154.32% | 59.95% | 47.07% | -134.82% | -236.41% |
Net Income | -4.48M | -46.87M | -90.03M | -163.01M | -46.81M | -74.41M | -61.69M | -50.42M | -51.64M | -43.42M |
Depreciation & Amortization | 218K | 9K | 5M | 7.68M | 6.31M | 4.5M | 5.87M | 6.02M | 8.74M | 7.02M |
Stock-Based Compensation | 586K | 6.97M | 9.52M | 10.58M | 9.58M | 10.83M | 16.46M | 22.25M | 20.7M | 9.62M |
Deferred Taxes | -7.25M | 65K | -15.05M | 25K | 15K | -18K | 5K | -21K | 21K | -6K |
Other Non-Cash Items | 2.46M | 11.36M | 17.99M | 51.25M | 9.06M | 8.44M | 11.24M | 10.77M | 2.39M | 4.67M |
Working Capital Changes | -2.11M | 2.79M | -20.81M | 35.6M | -11.54M | -34.25M | -5.89M | -6.6M | -22.48M | -14.34M |
Change in Receivables | 0 | 0 | -11.05M | -1.08M | -5.57M | -9.39M | -9.52M | -19.6M | -11.51M | -10.69M |
Change in Inventory | 0 | 0 | -4.48M | 4.54M | -2.98M | -10.69M | 4.19M | 3.25M | -11.12M | -15.17M |
Change in Payables | -2.43M | 1.27M | 183K | 2.32M | -787K | 968K | -1.02M | 391K | 10.1M | 5.38M |
Cash from Investing | 0 | -9K | -23.43M | 12.19M | 4.03M | -2.94M | -1.63M | -4.82M | -8.45M | -8.28M |
Capital Expenditures | 0 | -9K | -4.57M | -3.14M | -393K | -1.62M | -473K | -1.47M | 0 | -955K |
CapEx % of Revenue | - | - | 13.08% | 5.55% | 0.39% | 1.09% | 0.23% | 0.55% | 1.16% | 0.32% |
Acquisitions | 0 | 0 | 4.22M | 2.32M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -4.22M | -2.32M | -577K | -1.32M | -1.15M | -3.35M | -8.45M | -7.33M |
Cash from Financing | 13.04M | 118.84M | 133.55M | 38.35M | 73.05M | -4.15M | 44.64M | 47.41M | 17.34M | 26.59M |
Debt Issued (Net) | 14.32M | 0 | 72.86M | 39.48M | -24.36M | 0 | 50M | 0 | -15K | -15K |
Equity Issued (Net) | 0 | -239K | 73.31M | 0 | 103.34M | 0 | 0 | 51.21M | 1.16M | 404K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -1.29M | 119.08M | -12.63M | -1.13M | -5.92M | -4.15M | -5.36M | -3.8M | 16.19M | 26.2M |
Net Change in Cash | 0▲ 0% | 93.16M▲ 0% | 16.73M▼ 82.0% | -7.33M▼ 143.8% | 43.69M▲ 696.1% | -92.33M▼ 311.3% | 8.92M▲ 109.7% | 24.11M▲ 170.5% | -33.13M▼ 237.4% | -18.1M▲ 0% |
Free Cash Flow | -13.04M▲ 0% | -25.68M▼ 97.0% | -97.95M▼ 281.5% | -61.01M▲ 37.7% | -34.36M▲ 43.7% | -87.85M▼ 155.7% | -35.63M▲ 59.4% | -19.47M▲ 45.4% | -45.71M▼ 134.7% | -41.33M▲ 0% |
FCF Margin % | - | - | -280.46% | -107.9% | -34.47% | -59.11% | -17.63% | -7.31% | -15.38% | -13.71% |
FCF Growth % | 1.75% | -96.98% | -281.48% | 37.71% | 43.68% | -155.69% | 59.44% | 45.36% | -134.74% | -42.98% |
FCF per Share | -0.55 | -1.05 | -3.47 | -1.81 | -0.69 | -1.57 | -0.63 | -0.31 | -0.71 | -0.63 |
FCF Conversion (FCF/Net Income) | 2.91x | 0.55x | 1.04x | 0.36x | 0.71x | 1.14x | 0.55x | 0.36x | 0.82x | 0.95x |
Interest Paid | 0 | 0 | 5.17M | 7.24M | 138K | 8M | 12.71M | 17.55M | 0 | 10.74M |
Taxes Paid | 0 | 0 | 4K | 65K | 14K | 76K | 117K | 235K | 0 | 1.17M |
EOLS Key Ratios
Evolus, Inc. (EOLS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -113.31% | -5016.56% | -1049.79% | -148.27% | - | -913.08% | - | 174.92% |
Return on Invested Capital (ROIC) | -9.33% | - | -112.25% | -794.25% | -321.37% | -198.52% | -90.04% | -56.37% | -44.55% | -27.65% |
Gross Margin | - | - | 77.05% | 67.64% | 56.32% | 60.41% | 69.54% | 68.46% | 64.86% | 65.66% |
Net Margin | - | - | -257.79% | -288.31% | -46.96% | -50.07% | -30.52% | -18.94% | -17.38% | -14.41% |
Debt / Equity | - | - | 1.22x | - | 0.91x | 4.02x | - | 23.54x | - | -5.43x |
Interest Coverage | - | -53.23x | -12.21x | -14.51x | -32.50x | -6.33x | -3.45x | -1.66x | -1.91x | -1.92x |
FCF Conversion | 2.91x | 0.55x | 1.04x | 0.36x | 0.71x | 1.14x | 0.55x | 0.36x | 0.82x | 0.95x |
Revenue Growth | - | - | - | 61.89% | 76.29% | 49.1% | 35.98% | 31.76% | 11.61% | 9.42% |
Related:EOLS Dividend History·EOLS Revenue History·EOLS Price History·EOLS P/E History·EOLS Financial Ratios·EOLS Institutional Holders
EOLS SEC Filings & Documents
Evolus, Inc. (EOLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
EOLS Frequently Asked Questions
Evolus, Inc. (EOLS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Evolus, Inc. (EOLS) reported $301.4M in revenue for fiscal year 2025.
Evolus, Inc. (EOLS) grew revenue by 11.6% over the past year. This is steady growth.
Evolus, Inc. (EOLS) reported a net loss of $43.4M for fiscal year 2025.
Dividend & Returns
Evolus, Inc. (EOLS) had negative free cash flow of $41.3M in fiscal year 2025, likely due to heavy capital investments.